PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
PHXM was delisted on the 8th of March, 2024.
8 hedge funds and large institutions have $22.7M invested in PHAXIAM Therapeutics S.A.. American Depositary Shares in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 0 closing their positions.
14% more funds holding
Funds holding: 7 → 8 (+1)
56% less capital invested
Capital invested by funds: $51.6M → $22.7M (-$29M)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.25M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$730 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$20.8M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$879K |
| 3 |
Millennium Management
New York
|
-$43.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BBA
1
Baker Bros. Advisors
New York
| $9.31M | -$20.8M | -200,000 | -65% |
|
|
BI
2
BVF Inc
San Francisco,
California
| $5.45M | – | – | – |
|
|
NMC
3
NEA Management Company
Timonium,
Maryland
| $5.36M | – | – | – |
|
|
SFM
4
Sphera Funds Management
Tel Aviv,
Israel
| $1.05M | +$1.25M | +12,000 | New |
|
|
DG
5
Delek Group
Herzliya,
Israel
| $596K | – | – | – |
|
|
EC
6
EcoR1 Capital
San Francisco,
California
| $590K | -$879K | -8,439 | -55% |
|
|
7
Millennium Management
New York
| $299K | -$43.8K | -420 | -11% |
|
|
8
UBS Group
Zurich,
Switzerland
| $11K | +$730 | +7 | +6% |
|
PHXM Hedge Fund Activity: Q3 2018 in Review
8 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) for Q3 2018, worth a combined $22.7M — down 56% from $51.6M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new PHXM positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $1.25M. The largest seller was Baker Bros. Advisors, cutting an estimated $20.8M.
- 8 institutional investors held PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) as of Q3 2018, up from 7 in Q2 2018.
- Funds reported $22.7M of PHAXIAM Therapeutics S.A.. American Depositary Shares stock for Q3 2018, down 56% quarter-over-quarter.
- 1 fund opened new PHAXIAM Therapeutics S.A.. American Depositary Shares positions in Q3 2018 and 0 closed out, a net change of +1 holder.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares buyer in Q3 2018 was Sphera Funds Management, an estimated $1.25M added.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares seller in Q3 2018 was Baker Bros. Advisors, an estimated $20.8M sold.
Based on aggregated 13F filings for Q3 2018.